UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) June 19, 2013
Date of Report (Date of earliest event reported) May 2, 2013
HUBEI MINKANG PHARMACEUTICAL LTD. (Exact name of registrant as specified in its charter)
Nevada (State or other jurisdiction of incorporation	000-53231 (Commission File Number)	26-2410685 (IRS Employer Identification No.)

55 Ubi Ave. 3, #03-01, Mintwell Building
Singapore
(Address of principal executive offices)

408864

(Zip Code)

Registrant's telephone number, including area code +65-6747-7883

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CRF 240.13e-4(c))

SECTION 51 - ~~Corporate~~REGISTRANT'S ~~Governance~~BUSINESS ~~and~~AND ~~Management~~OPERATIONS

Item 51.~~02 Departure~~01 Entry ofinto ~~Directors~~a orMaterial ~~Certain~~Definitive ~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Agreement

~~Effective~~On ~~June~~May 192, 2013, ~~the~~our ~~board~~indirect ofwholly-owned ~~directors~~subsidiary, of Hubei Minkang Pharmaceutical Co., Ltd. (~~the~~"Hubei Minkang PRC"~~Company"~~), ~~accepted~~and ~~the~~Bank ~~resignations~~of Communications Co., Ltd., Yichang Branch, ("Bank of ~~Loke~~Communications") ~~Hip~~executed ~~Meng~~a asLiquid Capital Loan Contract (the ~~Chief~~"Loan ~~Financial~~Contract"), ~~Officer~~where ofHubei Minkang PRC arranged to loan RMB 10,000,000 (the ~~Company~~"Loan") to be used for purchasing medical materials and ~~Johnny~~paying ~~Lian~~for ~~Tian~~utilities, ~~Yong~~which asfunds awere ~~director~~withdrawn ofby ~~the~~Hubei ~~Company. Also~~Minkang ~~effective~~PRC on ~~June~~May 1917, 2013,. The ~~the~~Loan ~~board~~has ofa ~~directors~~term of ~~the~~one ~~Company~~year ~~accepted~~and ~~the~~is ~~consent~~due toon ~~act~~May as17, ~~Chief~~2014 ~~Financial~~having ~~Officer~~an interest rate of 6.6% per annum, which is calculated and paid on the ~~Company~~20th of ~~Lee~~each ~~Tong Tai~~month.

~~Mr.~~The ~~Lee~~foregoing ~~Tong~~description ~~Tai has been our President, Chief Executive Officer and a member~~ of ~~our~~Loan ~~board~~Contract ofdoes ~~directors~~not ~~since~~purport ~~September~~to ~~21,~~be ~~2011.~~complete ~~Mr.~~and ~~Lee~~is ~~graduated~~qualified ~~from Nanyang University~~ in ~~Singapore~~its ~~with~~entirety aby ~~Bachelor~~reference ofto ~~Commerce degree in 1978 majoring in Management and Finance. Mr. Lee launched his career with~~ the ~~Singapore~~Loan ~~Armed Forces (SAF) where from a cadet~~Contract, hewhich worked his way up and consequently held numerous key positions including Chief Engineer Officer of the Army and Chief of Staff of the 9th Singapore Combined Arms Division Mr. Lee served for 27 years in the SAF. In 2002, Mr. Lee incorporated Bizpoint International Ltd. where he is ~~the~~filed ~~Chairman and Chief Executive Officer. Bizpoint International Ltd. is in the business of providing IT solutions and software development tools for customers in various industries such~~ as ~~retail,~~Exhibit ~~manufacturing, food and beverage, logistings, chemical and others~~10.1 ~~Bizpoint International Ltd. is a public company quoted on the Singapore Over-The-Counter Platform and trades under the symbol "BP.OC". In 2005~~hereto, ~~Mr. Lee started a multi-faceted business named Sensori Holding(S) Pte. Ltd. which contained a pharmaceutical company in China, a dental chain, a spa institution~~ and ~~a distribution network of cosmetic products. Mr. Lee~~ is ~~the~~incorporated ~~Chairman and Chief Executive Officer of Sensori Holding(S) Pte. Ltd. The pharmaceutical company under Sensori Holdings was Hubei Minkang Pharmaceutical Co., Ltd., which was sold~~ by ~~Sensori~~reference ~~Holdings to HBMK Pharmaceutical Limited in October of 2010 as part of a restructuring plan~~herein. ~~Mr. Lee is the Deputy Chairman and a director of Hubei Minkang Pharmaceutical Co., Ltd.~~

AsThe aLoan ~~result~~Contract is secured maximum mortgage agreement No. A101430249 ("Maximum Mortgage Agreement #1") and maximum mortgage agreement No. DA101L130249-1 ("Maximum Mortgage Agreement #2"), both dated May 2, 2013, between Hubei Minkang PRC and Bank of Communications. Under the ~~changes~~Maximum ~~set~~Mortgage ~~forth~~Agreement ~~above~~#1, the ~~Company~~Loan Contract is collateralized by certain of Hubei Minkang PRC's ~~current~~land ~~directors~~use ~~and~~rights. Under ~~executive~~the ~~officers~~Maximum ~~are~~Mortgage asAgreement ~~follows:~~#2, the Loan Contract is collateralized by certain of Hubei Minkang PRC's buildings.

~~Name~~The ~~Position~~foregoing ~~Lee~~descriptions ~~Tong~~of ~~Tai~~Maximum ~~President,~~Mortgage ~~Chief~~Agreement ~~Executive~~#1 ~~Officer,~~and ~~Chief~~Maximum ~~Financial~~Mortgage ~~Officer~~Agreement #2 do not purport to be complete and aare ~~Director~~qualified ~~Ang~~in ~~Siew~~their ~~Khim~~entirety ~~Secretary~~by reference to the Maximum Mortgage Agreement #1, ~~Treasurer~~which is filed as Exhibit 10.2 hereto and athe ~~Director~~Maximum Mortgage Agreement #2, which is filed as Exhibit 10.3 hereto, both of which are incorporated by reference herein.

SECTION 2 - FINANCIAL INFORMATION

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

The disclosure under Item 1.01 of this Current Report on Form 8-K is responsive to this item and is incorporated by reference herein.

SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS

Item 9.01
Financial Statements and Exhibits

(a) Financial Statements of Business Acquired.

Not applicable.

(b) Pro Forma Financial Information.

Not applicable.

(c) Shell Company Transactions.

Not applicable.

(d) Exhibits.

Exhibit No. Description of Exhibit

10.1 Liquid Capital Loan Contract, dated May 2, 2013, among Hubei Minkang Pharmaceutical Co., Ltd. and Bank of Communications Co., Ltd., Yichang Branch, for RMB 10,000,000.

10.2 Maximum Mortgage Agreement No. A101430249, dated May 2, 2013, among Hubei Minkang Pharmaceutical Co., Ltd. and Bank of Communications Co., Ltd., Yichang Branch

10.3 Maximum Mortgage Agreement No. DA101L130249-1, dated May 2, 2013, among Hubei Minkang Pharmaceutical Co., Ltd. and Bank of Communications Co., Ltd., Yichang Branch

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: ~~June~~August 241, 2013

Hubei Minkang Pharmaceutical Ltd.

By:		/s/ Grace Ang
Name:		Grace Ang
Title:		Secretary, Treasurer and Director

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Filing Compare · Hubei Minkang Pharmaceutical Ltd.